Response to: ‘Association between osteoporosis and statins therapy’ by Lai
| Autor: | Caspar Matzhold, Michael Leutner, Peter Klimek, Stefan Thurner, Jürgen Harreiter, Carola Deischinger, Alexandra Kautzky-Willer, Luise Bellach |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry Immunology Osteoporosis nutritional and metabolic diseases Statin treatment medicine.disease General Biochemistry Genetics and Molecular Biology Rheumatology Bone Density Internal medicine JUPITER trial medicine Humans Immunology and Allergy lipids (amino acids peptides and proteins) In patient cardiovascular diseases Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Annals of the Rheumatic Diseases. 80:e181-e181 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2019-216494 |
| Popis: | We read with interest the correspondence of Lai .1 Whether statin therapy impacts the risk of osteoporosis is still a matter of debate. We have recently shown that there is a dose-dependent relationship between statins and diagnosis of osteoporosis; while low-dose statin treatment was related to an underrepresentation of diagnosed osteoporosis when compared with non-statin-treated patients, we found in patients on higher dosages of statins an overrepresentation of diagnosed osteoporosis in the general Austrian population.2 Although osteoporosis is often underdiagnosed until incident fractures, our data are based on diagnoses derived from in-patient treatment. Even though there are data available suggesting that some statins could have protective effects on osteoporosis,3 in the JUPITER trial, an international, randomised, double-blind and placebo-controlled study in which 17 802 patients were investigated, it has been shown that high-potency statin treatment did not reduce the risk of fractures.4 The fact that statin treatment might not only have positive … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|